Literature DB >> 16808748

Osteoporosis risk assessment and ethnicity: validation and comparison of 2 clinical risk stratification instruments.

Alvah R Cass1, Angela J Shepherd, Carol A Carlson.   

Abstract

BACKGROUND: Dual energy x-ray absorptiometry (DXA), coupled with early treatment, may reduce morbidity and mortality associated with osteoporosis. Clinical tools to enhance selection of women for DXA screening have not been developed or validated in an ethnically diverse population.
OBJECTIVE: To compare the performance of the osteoporosis risk assessment instrument (ORAI) and the simple calculated osteoporosis risk estimation (SCORE) instrument across 3 racial/ethnic groups to identify women who would benefit from DXA scans.
DESIGN: Blinded comparison of the instruments in a cross-sectional sample. PARTICIPANTS: Two-hundred twenty-six postmenopausal women were recruited from a university-based family medicine clinic. Women with a prior diagnosis of osteoporosis or those taking bone active medications were excluded. MEASUREMENTS: Participants completed a questionnaire that contained the ORAI and the SCORE questions; 203 completed a DXA scan.
RESULTS: The sensitivity and specificity for the ORAI (0.68, [0.49 to 0.88, 95% CI]; 0.66, [0.59 to 0.73, 95% CI]) and the SCORE instrument (0.54, [0.34 to 0.75, 95% CI]; 0.72, [0.65 to 0.78, 95% CI]) differed significantly from previous reports. Overall, the accuracy of the ORAI (66.5%) and SCORE instrument (70.0%) were similar (McNemar's test P value = .37). The accuracy between instruments differed significantly in African-American women (McNemar's test, P value <.001). In African Americans, the SCORE instrument correctly identified more women without osteoporosis, but missed 70% of those with osteoporosis.
CONCLUSIONS: The performance of the ORAI and SCORE instrument differed significantly from previous reports. Although both can reduce the use of DXA scans for screening for osteoporosis, lower sensitivities resulted in underrecognition of osteoporosis and may limit their clinical usefulness in an ethnically diverse population.

Entities:  

Mesh:

Year:  2006        PMID: 16808748      PMCID: PMC1924607          DOI: 10.1111/j.1525-1497.2006.00459.x

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN: 0884-8734            Impact factor:   5.128


  27 in total

1.  Do bisphosphonates reduce the risk of osteoporotic fractures? An evaluation of the evidence to date.

Authors:  Anthony B Hodsman; David A Hanley; Robert Josse
Journal:  CMAJ       Date:  2002-05-28       Impact factor: 8.262

2.  Screening for osteoporosis in postmenopausal women: recommendations and rationale.

Authors: 
Journal:  Ann Intern Med       Date:  2002-09-17       Impact factor: 25.391

Review 3.  Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group.

Authors: 
Journal:  World Health Organ Tech Rep Ser       Date:  1994

4.  Prevalence of low femoral bone density in older U.S. adults from NHANES III.

Authors:  A C Looker; E S Orwoll; C C Johnston; R L Lindsay; H W Wahner; W L Dunn; M S Calvo; T B Harris; S P Heyse
Journal:  J Bone Miner Res       Date:  1997-11       Impact factor: 6.741

5.  Comparison of alendronate and intranasal calcitonin for treatment of osteoporosis in postmenopausal women.

Authors:  R W Downs; N H Bell; M P Ettinger; B W Walsh; M J Favus; B Mako; L Wang; M E Smith; G J Gormley; M E Melton
Journal:  J Clin Endocrinol Metab       Date:  2000-05       Impact factor: 5.958

6.  Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.

Authors:  S T Harris; N B Watts; H K Genant; C D McKeever; T Hangartner; M Keller; C H Chesnut; J Brown; E F Eriksen; M S Hoseyni; D W Axelrod; P D Miller
Journal:  JAMA       Date:  1999-10-13       Impact factor: 56.272

Review 7.  Postmenopausal osteoporosis: fracture consequences and treatment efficacy vary by skeletal site.

Authors:  S Epstein
Journal:  Aging (Milano)       Date:  2000-10

8.  Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate/Estrogen Study Group.

Authors:  H G Bone; S L Greenspan; C McKeever; N Bell; M Davidson; R W Downs; R Emkey; P J Meunier; S S Miller; A L Mulloy; R R Recker; S R Weiss; N Heyden; T Musliner; S Suryawanshi; A J Yates; A Lombardi
Journal:  J Clin Endocrinol Metab       Date:  2000-02       Impact factor: 5.958

9.  Osteoporosis among estrogen-deficient women--United States, 1988-1994.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1998-11-20       Impact factor: 17.586

10.  Decreased incidence of hip fracture in Hispanics, Asians, and blacks: California Hospital Discharge Data.

Authors:  S L Silverman; R E Madison
Journal:  Am J Public Health       Date:  1988-11       Impact factor: 9.308

View more
  9 in total

Review 1.  Systematic review and meta-analysis of the performance of clinical risk assessment instruments for screening for osteoporosis or low bone density.

Authors:  S Nayak; D L Edwards; A A Saleh; S L Greenspan
Journal:  Osteoporos Int       Date:  2015-02-03       Impact factor: 4.507

2.  Clinical performance of seven prescreening tools for osteoporosis in Iranian postmenopausal women.

Authors:  Abbas Keshtkar; Omidreza Tabatabaie; Nassim Matin; Zahra Mohammadi; Mehdi Ebrahimi; Patricia Khashayar; Mojgan Asadi
Journal:  Rheumatol Int       Date:  2015-05-17       Impact factor: 2.631

3.  Development and internal validation of the male osteoporosis risk estimation score.

Authors:  Angela J Shepherd; Alvah R Cass; Carol A Carlson; Laura Ray
Journal:  Ann Fam Med       Date:  2007 Nov-Dec       Impact factor: 5.166

4.  Clinical performance of osteoporosis risk assessment tools in women aged 67 years and older.

Authors:  M L Gourlay; J M Powers; L-Y Lui; K E Ensrud
Journal:  Osteoporos Int       Date:  2008-01-25       Impact factor: 4.507

Review 5.  Risk Assessment Tools for Osteoporosis Screening in Postmenopausal Women: A Systematic Review.

Authors:  Carolyn J Crandall
Journal:  Curr Osteoporos Rep       Date:  2015-10       Impact factor: 5.096

6.  Comparison of three different osteoporosis risk assessment tools: ORAI (osteoporosis risk assessment instrument), SCORE (simple calculated osteoporosis risk estimation) and OST (osteoporosis self-assessment tool).

Authors:  Arman Ahmadzadeh; Mohammadmehdi Emam; Alireza Rajaei; Mohammad Moslemizadeh; Maryam Jalessi
Journal:  Med J Islam Repub Iran       Date:  2014-09-15

7.  Development and validation of osteoporosis prescreening model for Iranian postmenopausal women.

Authors:  Nassim Matin; Omidreza Tabatabaie; Abbasali Keshtkar; Kamran Yazdani; Mojgan Asadi
Journal:  J Diabetes Metab Disord       Date:  2015-03-17

8.  The relationship between sodium intake and some bone minerals and osteoporosis risk assessment instrument in postmenopausal women.

Authors:  Mohammadreza Vafa; Sepideh Soltani; Farid Zayeri; Mahtab Niroomand; Azadeh Najarzadeh
Journal:  Med J Islam Repub Iran       Date:  2016-05-28

9.  Risk assessment instruments for screening bone mineral density in a Mediterranean population.

Authors:  Sotirios Christodoulou; Georgios I Drosos; Athanasios Ververidis; Antonios Galanos; George Anastassopoulos; Konstantinos Kazakos
Journal:  World J Orthop       Date:  2016-09-18
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.